Consequences of Srsf2 P95H mutation on hematopoiesis in transplantation settings. (A) The percentage of CD45.2⁺ donor cells in the PB of WT and KI mice. Data are shown as mean ± SD from 3 independent experiments. The numbers of mice analyzed are n = 27 at 8 weeks and n = 21 at 16 weeks after transplantation. (B) The percentage of CFSE-positive cells in the BM of WT and KI mice at 16 hours after transplantation (mean ± SD, n = 5). (C) Left panel: absolute number of nucleated BM cells in bilateral femurs and tibias from WT and KI mice. Right panel: Section of femurs stained with hematoxylin and eosin. Scale bars, 400 μm. (D-H) Total cell number of donor-derived CD45.2⁺ CD34⁻KSLs and CD34⁺KSLs (panel D); KSL cells (panel E); LT-HSCs, MPPs, HPC-1, and HPC-2 (panel F); myeloid progenitors (panel G); and CLPs (panel H) in the BM (mean ± SD, n = 7). (I) Cell cycle analysis in donor-derived LT-HSCs and KSL cells using Ki-67 and Hoechst 33342 staining (mean ± SD, n = 6). (J) Percentage of apoptotic cells in donor-derived LT-HSCs and KSL cells (mean ± SD: WT, n = 10; KI, n = 9). (K) Percentages of myeloid (Gr-1⁺ and/or Mac-1⁺), B-lymphoid (B220⁺), and T-lymphoid (CD4⁺ and/or CD8⁺) cells in the donor-derived CD45.2⁺ nucleated BM cells (mean ± SD, n = 7). (L) Percentages of pre-pro B (CD19⁺ B220⁺ IgM⁻), immature B (CD19⁺ B220^mid IgM⁺), and mature B (CD19⁺ B220^high IgM⁺) populations in the donor-derived CD45.2⁺ nucleated BM cells (mean ± SD, n = 7). In panels C through L, mice were analyzed at 15 to 20 weeks after transplantation. *P < .05; **P < .01; ***P < .001; ****P < .0001. IgM, immunoglobulin M. KI, Srsf2 mutant transplanted mice; WT, wild-type transplanted mice.